Braun Stacey Associates Inc. Purchases New Shares in IQVIA Holdings Inc. $IQV

Braun Stacey Associates Inc. purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 69,628 shares of the medical research company’s stock, valued at approximately $11,874,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Boston Partners acquired a new stake in shares of IQVIA during the third quarter valued at about $676,698,000. Norges Bank acquired a new position in shares of IQVIA in the fourth quarter worth about $497,445,000. Victory Capital Management Inc. lifted its stake in shares of IQVIA by 2,628.1% in the fourth quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock worth $377,670,000 after acquiring an additional 1,614,063 shares in the last quarter. Orbis Allan Gray Ltd boosted its holdings in IQVIA by 96.5% in the fourth quarter. Orbis Allan Gray Ltd now owns 1,901,091 shares of the medical research company’s stock valued at $428,525,000 after purchasing an additional 933,554 shares during the last quarter. Finally, AQR Capital Management LLC grew its stake in IQVIA by 130.2% during the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after purchasing an additional 879,701 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of IQV opened at $191.12 on Friday. The business’s fifty day moving average price is $174.43 and its 200 day moving average price is $190.07. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $247.04. The stock has a market capitalization of $31.90 billion, a PE ratio of 23.68, a price-to-earnings-growth ratio of 1.64 and a beta of 1.21. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA announced that its board has authorized a stock repurchase program on Thursday, May 7th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

Several equities research analysts have issued reports on IQV shares. Weiss Ratings downgraded IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and raised their price target for the stock from $174.00 to $213.00 in a research report on Monday, March 9th. Wall Street Zen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday. Evercore reaffirmed an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a report on Wednesday, April 8th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $222.56.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.